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Cognitive Behavioural Therapy (CBT) is beneficial in depression. Symptom scores can be 
translated into Clinical Global Impression (CGI) scale scores to indicate clinical relevance.  
We aimed to assess the clinical relevance of findings of randomised controlled trials (RCTs) 
of CBT in depression. We identified RCTs of CBT that used the Hamilton Rating Scale for 
Depression (HAMD). HAMD scores were translated into Clinical Global Impression - 
Change scale (CGI-I) scores to measure clinical relevance. 170 data sets from 82 studies were 
included. The mean percentage HAMD change for treatment arms was 53.66%, and 29.81% 
for control arms, a statistically significant difference. Combined active therapies showed the 
biggest improvement on CGI-I score, followed by CBT alone. All active treatments, had 
better than expected HAMD percentage reduction and CGI-I scores. CBT has a clinically 






















1.1 Depressive disorders are common throughout the world. They are by far the most 
common cause of Years Lost due to Disability in high-, as well as low- and middle-, income 
countries, in both men and women (Murray & Lopez, 1996). Antidepressants and a range of 
psychological therapies have been shown to be beneficial in the treatment of depression and 
are recommended in treatment guidelines (American Psychiatric Association, 2000; National 
Institute for Clinical Excellence, 2009; Ellis Royal Australian & New Zealand College of 
Psychiatrists Clinical Practice Guidelines Team for Depression, 2004). People suffering from 
depression often prefer psychological treatments to medication (Prins et al, 2008). There is 
variation in individual responses to treatment, including long-term outcome. A range of 
psychotherapeutic interventions have been developed and refined to improve treatment 
outcomes (Ellis Royal Australian & New Zealand College of Psychologists Clinical Practice 
Guidelines Team for Depression, 2004). Clinical trials of psychotherapies suggest that 
differences between these treatments are small and may have little clinical significance 
(Cuijpers et al, 2008).  
 
1.2 Previous research has explored the relationship between changes in commonly used 
symptom rating scales and clinical improvement.  Based on data from clinical trials, 
statistical methods to convert symptom scores into notional Clinical Global Impression scale 
severity and change (CGI–S and CGI–C/CGI-I) scores have been developed (Leucht et al, 
2005; Lepping et al, 2011; Leucht et al, 2013). These two scales quantify clinician's’ overall 
impression of clinical severity and clinical change in participants’ psychiatric condition with 
an aim to bring clinical relevance into trial results. The conversion helps in understanding the 
relationship between statistically significant results and meaningful clinical improvement.  
 
1.3 Using a published systematic database of randomized trials of psychotherapies for adult 
depression (Cuijpers et al, 2011), we aimed to assess the clinical relevance of outcomes 
reported for cognitive behavioural therapy trials in depression. We used a broad definition of 
CBT therapies, which includes cognitive bibliotherapy, but not behavioural activation 
therapy. We used a notional CGI translation of scores from the Hamilton Rating Scale for 
Depression (HAMD), (Guy W (Ed): ECDEU Assessment Manual for Psychopharmacology. 
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one of the most commonly used scales in CBT clinical trials (Leucht et al, 2013; Hamilton, 
1967). 
 
Material and Methods 
2.1 We searched a comprehensive database of randomised controlled clinical trials of 
psychological therapies for depression (Cuijpers et al 2011; Van’t Hof et al, 2011). A detailed 
description of the development of this database has been published and can be accessed 
online (www.evidencebasedpsychotherapies.org) (Cuijpers et al, 2008). Systematic review 
principles were used to include all possible RCT trials using CBT for the treatment of 
depression. 
2.2 The inclusion criteria for our review were: 
● Participants: a diagnosis of depression with no psychiatric or physical co-morbidity. 
● Interventions: At least one type of psychological therapy classified in the database as 
CBT 14 
● Comparator: any comparator or control. Any arm with a placebo is classed as a 
control  
● Outcome measures: percentage change in mean Hamilton depression rating scale 
(HAMD/HDRS) score, given directly or calculated from baseline to endpoint data  
● Design: randomised controlled trial. 
● Reporting:  
o published in a peer reviewed journal and included in the database up to 
31.12.2013, the point to which the data base was complete at the time of the 
study. Books and conference posters were excluded. 
o published in any language. 
o sample size for each study arm reported 
o available as electronic full-text or as paper full-text.  
 
2.3 We obtained the full text version of identified papers. Data were extracted by two 
reviewers independently (RSS & RW) and differences were resolved by consensus. Leucht 
and colleagues have demonstrated that changes in HAMD scales can be translated into 
notional Clinical Global Impressions scale, severity and improvement (CGI-S and CGI-I) 
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scores (Table 1) (Leucht et al, 2013). The method used for the translation was equi-percentile 
linking of HAMD-17 and CGI ratings from 43 drug trials in patients with Major Depressive 
Disorder (MDD) treated with mirtazapine (n=7,131). This method has some limitations, but 
generates an acceptably robust translation, allowing an objective and reliable estimate of the 
clinical relevance of published findings. The same or similar methods have been used to 
evaluate clinical relevance of antipsychotic trial data (Lepping et al, 2011), Transcranial 
Magnetic Stimulation trial data (Lepping et al, 2014), antidepressant trial data (Moncrieff  & 
Kirsh, 2015), and Cognitive Therapies for schizophrenia trial data (Kontis et all, 2014). 
Table 1 about here 
2.4 To determine the CGI ratings from the reported HAMD data in our analysis, the mean 
percentage change from baseline to the last follow-up point was calculated for each study 
using an Excel spreadsheet. An overall mean percentage change was then calculated for 
aggregated treatment and control arms, as well as subgroups of particular treatments and 
control conditions. Hypothesis tests were carried out using the independent sample t-test, at 
the 5% significance level to access the statistical significant of mean percentage change 
between CBT subgroup and the remaining four subgroups. The percentage HAMD change 
was plotted with CGI-I scores on a graph. The CGI-I score was extracted manually for each 
point (PL), as the conversion graphs are not linear (Leucht et al, 2013). 
2.5 The database classifies a therapy as CBT when cognitive restructuring (the evaluating, 
challenging, and modifying a patient’s dysfunctional beliefs) was one of the core elements of 
the therapy. The subgroups are classified in accordance with the database. The study arms 
were categorised in discussion with the research team. The included studies are of diverse 
quality. They have different degrees of blinding or no blinding at all. Whilst all were RCTs, 
the recruitment processes were variable and may have relied on volunteers recruited by 
advertisements. This is in keeping with shortcomings of the psychotherapy literature in 
general, which are well described (National Institute for Clinical Excellence, 2009). Study 
arms were classified into five subgroups:  
1. CBT alone (n=61 study arms).  See above for definition criteria. 
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2. Other psychological mono-therapy (n=57). This group includes a variety of active 
psychotherapies, including behavioural activation, provided only one therapy is 
applied to that group of participants.  
3. Pharmacological mono-therapy (n=21). This group includes any antidepressant 
therapy where only one active drug was used. 
4. Combinations of active therapies (n=31). This group includes any combination of 
therapies, whether psychological or medication. 
5.  Controls (n=44), this group includes waiting list controls, treatment as usual and 
placebo. 
For a comprehensive list of the included study arms and their categorization see the list of 
included studies or contact the authors. 
Results 
3.1 The database was accessed on in December 2013 generating 421 titles (Fig. 1).  In the 
next stage we excluded duplicates and papers with insufficient data. We obtained full-text 
versions of the remaining 393 papers, of which a further 311 were excluded. The remaining 
82 papers were included in the analysis. Overall raw disagreement between the two 
independent extractors occurred with 13.7% data points. All disagreements were identified 
and resolved by re-extracting the data. The 82 studies included had between 2 and 10 study 
arms, yielding 170 datasets relating to a psychological therapy. By adding control arms, a 
total of 214 datasets were included in the analysis. These datasets included 6330 individual 
participants. HAMD scores at baseline confirmed that the participants met research criteria 
for depression, above the accepted threshold score of 8 or higher.  
 
Figure 1 about here 
3.2 Table 2 shows the mean percentage change in HAMD scores and the translation into 
notional CGI–I scores for all five categories. The mean percentage HAMD change for the 
aggregated treatment arms was 53.66%, and 29.81% for aggregated control arms. This 
difference was statistically significant (p<0.05). The notional CGI-I score for treatment was 
2.25 (1=”very much improved”, 2=”much improved”, 3=”minimally improved”, 4=”no 




Table 2 about here 
 
Amongst the different types of psychological and pharmacological treatments, the notional 
CGI-I score was lowest for the category “combination of active therapies”, indicating the 
biggest clinical improvement. This was followed by “CBT alone”, followed by “other 
psychological mono-therapies” and “pharmacological mono-therapies”. Compared to “CBT 
alone”, the HAMD percentage change of the category “combination of active therapies” 
showed statistical significance in favour of the “combination of active therapies”. “CBT 
alone” showed statistically significant superiority to “controls” and “other pharmacological 
mono-therapies”. It was not superior to “other psychological mono-therapies” (see table 3). 
 
Table 3 about here 
 
3.3 A large sample size was taken as proxy for high quality study.  In order to exclude the 
possibility that the inclusion of many small datasets exaggerated differences in CGI-I scores, 
we compared the 10 largest datasets with the rest. The 10 largest studies showed a 3% lower 
HAMD percentage change than the rest of the studies (51.6% versus 54.7%). This equated to 
a CGI-I score difference of 0.15 (2.3 versus 2.15). We compared findings according to the 
version of HAMD used. The majority of treatment arms (142) used the 17-item version 
(HAMD17). Notional CGI-I scores were marginally higher for the 26-item version (used in 
only one study), but there were no differences between the other three versions. All 




4.1 Following the method of previous reviews (Lepping et al, 2011; Lepping et al, 2014; 
Moncrieff & Kirsch, 2015; Kontis et al, 2014), we translated percentage change in HAMD 
scores into notional CGI-I scores for psychological therapies in depression. The results 
indicate that there is a significant and clinically relevant effect of CBT, with a notional CGI-I 
score of 2.2, indicating that participants were, on average, close to the threshold for being 
“much improved”. CBT based therapies compared well to other psychological and 
pharmacological therapies. Only the combination of active therapies showed better results. 
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The advantage of CBT alone compared to antidepressants alone was statistically significant 
but below the threshold of clinical relevance (CGI-I difference: 0.15 or 4.36% difference in 
HAMD score change). CBT was superior to control conditions (CGI-I difference: 0.9, 
HAMD percentage change difference: 24.21%). The control improvement represents a large 
placebo effect. The difference between CBT and other psychological mono-therapies was not 
statistically significant (CGI-I difference: 0.05, HAMD percentage change difference: 
1.05%). It therefore appears that the main difference between psychotherapies is how change 
is achieved, not in the degree of change. Our results suggest important implications for 
clinicians and service providers, but interpretation of the findings should be cautious. CBT is 
labour intensive, expensive and requires cooperation from patients over several months. 
Combinations of active therapies, mainly CBT with antidepressant medication, appears 
superior to CBT alone, and this may therefore be the most desirable treatment choice.   
 
4.2 The similarity in results for all treatments and combinations, notwithstanding some 
statistically significant differences, may be a consequence of the small sample sizes in the 
majority of trials of psychological treatments. Furthermore, there are far more trials of CBT 
than any other psychological intervention. These shortcomings in the evidence base may 
militate against capturing differences in clinical effects. It is known that there is significant 
publication bias in the psychotherapy literature (Cuijpers et al, 2010), and that this may be 
greater than the corresponding bias in the antidepressant literature. Huhn and colleagues have 
pointed towards shortcomings in the psychotherapy literature and study designs. They 
concluded that there are few differences in effect size between medication and 
psychotherapy. They concluded that whilst effect sizes of psychotherapies versus placebo 
tended to be higher than those of medication, direct comparisons did not reveal consistent 
differences. Individual pharmacotherapy trials were more likely to have large sample sizes, 
blinding, control groups, and intention-to-treat analyses. Psychotherapy trials had lower 
dropout rates and provided follow-up data (Huhn et al, 2014). They concluded that many 
pharmacotherapies and psychotherapies are effective, but there is much room for 
improvement. Because of the multiple differences in the methods used in pharmacotherapy 
and psychotherapy trials, indirect comparisons of their effect sizes compared with placebo or 
no treatment are problematic. The same applies to our current analysis. It would be 
inappropriate to conclude from it that psychotherapy is necessarily more effective than 
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antidepressants. Well-designed direct comparisons, which are scarce, require public funding, 
which is scarce (Huhn et al, 2014). 
 
4.3 How do our results compare with other studies? The UK Improving Access to 
Psychological Therapies project (IAPT) claims a 46.1% recovery rate for those completing 
treatment. However, few referred patient actually completed the whole course of treatment 
(http://www.iapt.nhs.uk/silo/files/iapt-3-year-report.pdf). Other primary care studies have 
found that the best remission rates with antidepressants are no higher than 47% (Ramsberg et 
al, 2012). Even when stringent response criteria are used, such as a CGI-I of 2 (equivalent to 
a percentage HAMD change of -59%), our results show good response rates in CBT arms for 
the average participant. In the pharmacological arms, with a mean HAMD change of 49.66%, 
the average participant responded (using the common industry response criteria of a HAMD 
reduction of 50%). In these CBT trials, the rate of response to antidepressants far exceeds 
response rates in drug trials designed to test the effects of antidepressants. Even when we take 
into account the publication bias in psychotherapy trials, these results are in excess of 
expectations. It raises the question whether being part of a psychotherapy trial has a large 
placebo effect. In our analysis the non-specific or placebo effect of being in a psychotherapy 
trial is 29% reduction in HAMD, which is substantial. Another explanation might be that 
usual remission criteria have limitations. Zimmerman and colleagues recently found that half 
of all patients with a HAMD below 7, which is normally considered as remission, did not 
consider themselves to be in remission and had at least one residual symptom (Zimmerman et 
al, 2012). The unusual efficacy found in all treatment arms in the psychotherapy literature is a 
finding that demands further exploration.  
4.4 We sourced our studies from a database of psychotherapy trials that finished at the end of 
2013. The database we used is exceptional in its meticulous attempt to cover all published 
trials, but nonetheless we may have missed some studies. Although a large number of 
datasets were included in the analysis, 52 studies had to be excluded for reporting data in the 
wrong format. The CBT literature is very heterogeneous. With regards to our analysis, a 
limitation is that we break randomisation, analyse the different arms individually and then 
compare them again, instead of first calculating differences between interventions in 
individual studies and summarising them at the end. This is inherently necessary in our 
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methodology. Although a limitation, the method nonetheless provides a perspective of the 
evidence that is useful in drawing conclusions about clinical usefulness. 
 
4.5 Our method of converting HAMD continuous scores into CGI categorical scores is based 
on translating of psychometrically validated HAMD scores into impressionistic CGI scales 
by utilising conversion graphs that are not perfectly linear. Based on previous studies, we 
have reported CGI-I scores to 0.05 differences, to illustrate the proximity of results to 
thresholds on the CGI-I. Studies used different lengths of treatment, the majority between 3 
or 6 months in duration. We have not examined length of treatment as a factor affecting 
outcome. 
 
4.6 There are variations in the extent to which psychological therapies follow strict CBT 
procedures. Some modifications of CBT create therapies that are markedly different to the 
therapy described by Beck. There is no standard measure of fidelity of interventions to the 
CBT model. There was no alternative but to accept authors’ statements that treatments were a 
form of CBT. Many papers did not describe content of therapy in detail.  
 
Conclusion 
5.1 In conclusion, our findings show that there is a significant and clinically relevant effect 
when using CBT for depression, with a notional CGI-I score of 2.2 indicating a good clinical 
response. This supports the continuing use of the therapy for this disorder. Our study 
underlines that statistically significant improvements on specific instruments need to be 
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-84% 1 Very much improved 
-59% 2 Much improved 
-33% 3 Minimally improved 
-9% 4 No change 
+8% 5 Minimally worse 
+27.5%
  
6 Much worse 
+60% 7 very much worse 
 
Table 2: Results for each treatment cluster 
 





















       



























       










Table 3: Hypothesis tests 
Comparator 
1 






CBT Control 24.21 45.25 Yes 
CBT Combination of active 
therapies  
-3.56 -6.36 Yes 
CBT Other psychological 
mono-therapy 
1.05 1.85 No 
CBT Pharmacological mono-
therapy  
4.36 7.78 Yes 
 T=1.98 implies statistically significant difference between groups   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
